Saladax Biomedical develops novel diagnostic tests for the practical delivery of personalized medicine and development of companion diagnostics.
Our initial focus for the MyCare assays is in
the oncology field, with tests that measure chemotherapy drug levels in blood using proprietary monoclonal antibodies bound to nanoparticles. The majority of these antibodies are the first ever developed to the drugs in question.
The practice of dose optimization through therapeutic drug management is routine in many fields of medicine, including neurology, cardiology, and transplantation, but it has not been prevalent in oncology. Typically, the criteria used to select drugs as good monitoring candidates apply very aptly to chemotherapy agents. These include:
- A highly variable relationship between dose and resulting individual blood concentration
- A relationship between the drug blood concentration and the desired and/or undesired effect
- A narrow therapeutic window, and
- Dose-limiting toxicity.
Saladax has a portfolio of thirteen assays in oncology and two in anti-psychotics that are in various stages of development:
FOR ADDITIONAL INFORMATION ON ANY SALADAX PRODUCTS, PLEASE CONTACT:
Keith GallowayVice President, Marketing & Sales
Saladax Biomedical, Inc
116 Research Drive
Bethlehem, PA 18015
E-mail:
kgalloway@saladax.comPhone: (610) 419-6731 ext 26517
Fax: (610) 849-5001